HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Liver-specific loss of lipolysis-stimulated lipoprotein receptor triggers systemic hyperlipidemia in mice.

AbstractOBJECTIVE:
In mammals, proper storage and distribution of lipids in and between tissues is essential for the maintenance of energy homeostasis. In contrast, aberrantly high levels of triglycerides in the blood ("hypertriglyceridemia") represent a hallmark of the metabolic syndrome and type 2 diabetes. As hypertriglyceridemia has been identified as an important risk factor for cardiovascular complications, in this study we aimed to identify molecular mechanisms in aberrant triglyceride elevation under these conditions.
RESEARCH DESIGN AND METHODS:
To determine the importance of hepatic lipid handling for systemic dyslipidemia, we profiled the expression patterns of various hepatic lipid transporters and receptors under healthy and type 2 diabetic conditions. A differentially expressed lipoprotein receptor was functionally characterized by generating acute, liver-specific loss- and gain-of-function animal models.
RESULTS:
We show that the hepatic expression of lipid transporter lipolysis-stimulated lipoprotein receptor (LSR) is specifically impaired in mouse models of obesity and type 2 diabetes and can be restored by leptin replacement. Experimental imitation of this pathophysiological situation by liver-specific knockdown of LSR promotes hypertriglyceridemia and elevated apolipoprotein (Apo)B and E serum levels in lean wild-type and ApoE knockout mice. In contrast, genetic restoration of LSR expression in obese animals to wild-type levels improves serum triglyceride levels and serum profiles in these mice.
CONCLUSIONS:
The dysregulation of hepatic LSR under obese and diabetic conditions may provide a molecular rationale for systemic dyslipidemia in type 2 diabetes and the metabolic syndrome and represent a novel target for alternative treatment strategies in these patients.
AuthorsPrachiti Narvekar, Mauricio Berriel Diaz, Anja Krones-Herzig, Ulrike Hardeland, Daniela Strzoda, Sigrid Stöhr, Marcus Frohme, Stephan Herzig
JournalDiabetes (Diabetes) Vol. 58 Issue 5 Pg. 1040-9 (May 2009) ISSN: 1939-327X [Electronic] United States
PMID19188430 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Apolipoproteins E
  • Blood Glucose
  • Fatty Acids, Nonesterified
  • Ketone Bodies
  • Lipoproteins, VLDL
  • Receptors, LDL
  • Receptors, Lipoprotein
  • Triglycerides
  • lipolysis-stimulated receptor
  • Cholesterol
Topics
  • Animals
  • Apolipoproteins E (deficiency)
  • Blood Glucose (metabolism)
  • Cholesterol (blood)
  • Diabetes Mellitus, Experimental (physiopathology)
  • Diabetes Mellitus, Type 2 (physiopathology)
  • Disease Models, Animal
  • Fatty Acids, Nonesterified (blood)
  • Hyperlipidemias (physiopathology)
  • Ketone Bodies (blood)
  • Lipolysis
  • Lipoproteins, VLDL (metabolism)
  • Liver (physiology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Obese
  • RNA Interference
  • Receptors, LDL (deficiency, genetics, physiology)
  • Receptors, Lipoprotein (physiology)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: